Merus to Participate in Upcoming Investor Conferences

Rhea-AI Summary

On February 1, 2021, Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in upcoming investor conferences. Key events include the Guggenheim Healthcare Talks 2021 Oncology Days on February 12, LifeSci Partners Precision Oncology Day on February 17, and the 2021 SVB Leerink Global Healthcare Conference on February 26. Webcasts of the presentations will be accessible via the Company’s Investors page, with archived versions available for a limited time.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:

Guggenheim Healthcare Talks 2021 Oncology Days (Fireside chat): Friday, Feb. 12 at 10:30-10:55 a.m. ET

LifeSci Partners Precision Oncology Day (Presentation): Wednesday, Feb. 17 at 10:30-10:55 a.m. ET

2021 SVB Leerink Global Healthcare Conference (Presentation): Friday, Feb. 26 at 8:40-9:10 a.m. ET

The live webcasts of the presentations will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and
https://twitter.com/MerusNV.

FAQ

What are the upcoming conferences where Merus N.V. (MRUS) CEO will speak?

Merus N.V. CEO Bill Lundberg will speak at the Guggenheim Healthcare Talks on February 12, LifeSci Partners Precision Oncology Day on February 17, and the SVB Leerink Global Healthcare Conference on February 26.

When is the Guggenheim Healthcare Talks 2021 Oncology Days conference?

The Guggenheim Healthcare Talks 2021 Oncology Days conference will take place on February 12, 2021, at 10:30 a.m. ET.

How can I access the presentations from Merus N.V. (MRUS)?

Presentations from Merus N.V. can be accessed via live webcasts on the Company’s Investors page and will also be available as archived versions for a limited time.

What type of company is Merus N.V. (MRUS)?

Merus N.V. is a clinical-stage oncology company developing innovative bispecific and trispecific antibody therapeutics, known as Multiclonics.

What is the focus of Merus N.V.'s research?

Merus N.V. focuses on developing full-length multispecific antibodies aimed at treating various types of cancer.